A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses-Reference-Cited by-同舟云学术

A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses

Published:2014-10-15 Issue:6 Volume:74 Page:1261-1270
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Cohen E. E. W.,Tortorici M.,Kim S.,Ingrosso A.,Pithavala Y. K.,Bycott P.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-014-2604-8/fulltext.html

Reference38 articles.

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917

2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, Zhang Y (2009) International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 20(5):525–531

3. La Vecchia C, Bosetti C, Lucchini F, Bertuccio P, Negri E, Boyle P, Levi F (2010) Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 21(6):1323–1360

4. Simard EP, Ward EM, Siegel R, Jemal A (2012) Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 62(2):118–128. doi: 10.3322/caac.20141

5. Klein M, Picard E, Vignaud JM, Marie B, Bresler L, Toussaint B, Weryha G, Duprez A, Leclere J (1999) Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endocrinol 161(1):41–49

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tyrosine Kinase Inhibitors for Radioactive Iodine Refractory Differentiated Thyroid Cancer;Life;2023-12-22

2. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy;Drug Resistance Updates;2023-05

3. Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer;Thyroid Research;2023-03-01

4. Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy;The Chemical Record;2022-09-14

5. Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer;Frontiers in Endocrinology;2022-09-08